Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Historic Other Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 3 years, with Q3 2021 value amounting to $796000.0.

  • Nurix Therapeutics' Other Non-Current Liabilities fell 829.49% to $796000.0 in Q3 2021 from the same period last year, while for Aug 2021 it was $796000.0, marking a year-over-year decrease of 829.49%. This contributed to the annual value of $850000.0 for FY2020, which is 5106.51% down from last year.
  • Nurix Therapeutics' Other Non-Current Liabilities amounted to $796000.0 in Q3 2021, which was down 829.49% from $837000.0 recorded in Q2 2021.
  • In the past 5 years, Nurix Therapeutics' Other Non-Current Liabilities registered a high of $1.7 million during Q4 2019, and its lowest value of $796000.0 during Q3 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $843500.0 (2020), whereas its average is $986666.7.
  • As far as peak fluctuations go, Nurix Therapeutics' Other Non-Current Liabilities tumbled by 5106.51% in 2020, and later crashed by 829.49% in 2021.
  • Nurix Therapeutics' Other Non-Current Liabilities (Quarter) stood at $1.7 million in 2019, then plummeted by 51.07% to $850000.0 in 2020, then dropped by 6.35% to $796000.0 in 2021.
  • Its Other Non-Current Liabilities stands at $796000.0 for Q3 2021, versus $837000.0 for Q2 2021 and $832000.0 for Q1 2021.